HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a response Alert me when this article is cited Alert me when Rapid Responses are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Personius, K. E Search for Related Content PubMed PubMed Citation Articles by Personius, K. E Related Collections Muscular Dystrophy Tests and Measurements Social Bookmarking                      What's this?

Facioscapulohumeral Dystrophy Natural History Study: Standardization of Testing Procedures and Reliability of Measurements

KE Personius, PT, is a doctoral student in the Physiological Sciences Program, University of Arizona, Tucson, AZ 85721. He was Staff Physical Therapist, Department of Neurology, University of Rochester, Rochester, NY 14642, when this study was conducted.
S Pandya, PT, is Assistant Professor, Department of Neurology, University of Rochester, and Department of Physical Therapy, Ithaca College, Rochester Campus, 300 E River Rd, Rochester, NY 14623 (USA).
WM King, PT, is Therapy Supervisor, Muscular Dystrophy Clinic, Department of Neurology, Ohio State University, Columbus, OH 43210.
R Tawil, MD, is Assistant Professor, Department of Neurology, University of Rochester.
MP McDermott, PhD, is Assistant Professor, Departments of Biostatistics and Neurology, University of Rochester.
Other members of the FSH DY Group are Jerry R Mendell, MD, John Kissell, MD, and Fran Rainey (Ohio State University); Robert C Griggs, MD, Richard T Moxley III, MD, Diane Storvick, Lynn Cos, RN, William Martens, Sandra Plumb, Carol Bragg, Nancy Giampietro, and Barbara Herr (University of Rochester).

Background and Purpose. The natural history of facioscapulohumeral muscular dystrophy (FSHD) has not been studied prospectively. Knowledge of the natural progression of any disease provides essential information for the design of clinical trials. We present a protocol for the study of the natural history of FSHD using quantitative muscle testing (QMT), manual muscle testing (MMT), and functional testing. Subjects. Thirty-two persons with FSHD (mean age=36.1 years, SD=9.6, range=17–49) and 32 age- and gender-matched volunteer controls (mean age=35.8 years, SD=8.0, range=23–50) served as subjects. Methods. Using standardized testing procedures, we examined intrarater reliability of the MMT, QMT, and functional testing measurements in both groups. We also examined interrater reliability in 7 subjects with FSHD. Eighteen muscle groups were tested for each subject using QMT and MMT. Results. Intraclass correlation coefficient (ICC) values ranged from .86 to .99 for intrarater reliability and from .86 to .99 for interrater reliability of QMT measurements. Weighted kappa values of .81 to .98 for intrarater reliability and .50 to 1.00 for interrater reliability were obtained for MMT measurements. Intrarater ICCs for various functional testing measures ranged from .60 to .97. In addition, the comparability of the two QMT machines used in the study was demonstrated by testing the same set of volunteer controls on each machine's linear force transducer (ICC=.89–.98). Conclusion and Discussion. We conclude that this standardized testing protocol produces reliable measurements of muscle strength and functional ability in subjects with FSHD.

Key Words: Facioscapulohumeral muscular dystrophy • Functional testing • Isometric muscle testing • Manual muscle testing

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. R. Rose, M. K. Sharief, J. Priddin, V. Nikolaou, L. Hull, C. Unwin, R. Ajmal-Ali, R. A. Sherwood, A. Spellman, A. David, et al. Evaluation of neuromuscular symptoms in UK Gulf War veterans: A controlled study Neurology, November 9, 2004; 63(9): 1681 - 1687. [Abstract] [Full Text] [PDF]

				E.L. van der Kooi, O.J.M. Vogels, R.J.G.P. van Asseldonk, E. Lindeman, J.C.M. Hendriks, M. Wohlgemuth, S.M. van der Maarel, and G.W. Padberg Strength training and albuterol in facioscapulohumeral muscular dystrophy Neurology, August 24, 2004; 63(4): 702 - 708. [Abstract] [Full Text] [PDF]

				The Muscle Study Group Randomized pilot trial of high-dose {beta}INF-1a in patients with inclusion body myositis Neurology, August 24, 2004; 63(4): 718 - 720. [Abstract] [Full Text] [PDF]

				Randomized pilot trial of {beta}INF1a (Avonex) in patients with inclusion body myositis Neurology, November 13, 2001; 57(9): 1566 - 1570. [Abstract] [Full Text] [PDF]

				J. T. Kissel, M. P. McDermott, J. R. Mendell, W. M. King, S. Pandya, R. C. Griggs, and R. Tawil Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy Neurology, October 23, 2001; 57(8): 1434 - 1440. [Abstract] [Full Text] [PDF]

				M. Stangel, F. Boegner, C. H Klatt, C. Hofmeister, and S. Seyfert Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, January 1, 2000; 68(1): 89 - 92. [Abstract] [Full Text]

				S. R. Schwid, C. A. Thornton, S. Pandya, K. L. Manzur, M. Sanjak, M. D. Petrie, M. P. McDermott, and A. D. Goodman Quantitative assessment of motor fatigue and strength in MS Neurology, September 1, 1999; 53(4): 743 - 743. [Abstract] [Full Text] [PDF]

				C. T. Bever JR, P. A. Anderson, G. V. Smith, H. S. Panitch, and K. P. Johnson Isometric Measurement of Hamstrings and Quadriceps Strength in Multiple Sclerosis Patients: Sensitivity and Variability Neurorehabil Neural Repair, January 1, 1995; 9(4): 221 - 227. [Abstract] [PDF]